Research programme: mutilin-quinolone hybrid antibacterials - Kyorin

Drug Profile

Research programme: mutilin-quinolone hybrid antibacterials - Kyorin

Alternative Names: AM-3005; Compound 25 (AM-3005) - Kyorin; Mutilin-quinolone hybrids - Kyorin

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyorin Pharmaceutical
  • Class Fluoroquinolones; Ketones; Polycyclic compounds
  • Mechanism of Action Protein synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in Japan (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Japan (Parenteral)
  • 10 Nov 2008 Preclinical trials in Gram-positive infections in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top